GH Research (NASDAQ:GHRS) Earns “Buy” Rating from HC Wainwright

GH Research (NASDAQ:GHRS)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $40.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 376.19% from the stock’s current price.

Separately, Canaccord Genuity Group decreased their price target on GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, November 18th.

GH Research Stock Down 6.5 %

Shares of GHRS traded down $0.58 during trading on Friday, reaching $8.40. The company’s stock had a trading volume of 82,044 shares, compared to its average volume of 128,287. GH Research has a twelve month low of $5.50 and a twelve month high of $14.99. The company has a market cap of $437.04 million, a price-to-earnings ratio of -10.63 and a beta of 0.84. The company has a fifty day moving average of $8.43 and a two-hundred day moving average of $9.23.

Institutional Investors Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. increased its stake in GH Research PLC (NASDAQ:GHRS) by 1.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,686,689 shares of the company’s stock after purchasing an additional 85,000 shares during the period. RA Capital Management L.P. owned 12.85% of GH Research worth $44,734,000 at the end of the most recent reporting period. Institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).